VIATRIS: A New Champion for Global Health

January 2020 Investor Presentation
Forward-Looking Statements

This communication contains “forward-looking statements”. Such forward-looking statements may include, without limitation, statements about the proposed combination of Upjohn Inc. (“Newco”) and Mylan N.V. (“Mylan”), which will immediately follow the proposed separation of the Upjohn business (the “Upjohn Business”) from Pfizer Inc. (“Pfizer”) (the “proposed transaction”), the expected timetable for completing the proposed transaction, the benefits and synergies of the proposed transaction, future opportunities for the combined company and products and any other statements regarding Pfizer’s, Mylan’s, the Upjohn Business’s or the combined company’s future operations, financial or operating results, capital allocation, dividend policy, debt ratio, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competitions, and other expectations and targets for future periods. Forward-looking statements may often be identified by the use of words such as “will”, “may”, “could”, “should”, “would”, “project”, “believe”, “anticipate”, “expect”, “plan”, “estimate”, “forecast”, “potential”, “pipeline”, “intend”, “continue”, “target”, “seek” and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the parties’ ability to meet expectations regarding the timing, completion and accounting and tax treatments of the proposed transaction; changes in relevant tax and other laws; the parties’ ability to consummate the proposed transaction; the conditions to the completion of the proposed transaction, including receipt of approval of Mylan’s shareholders, not being satisfied or waived on the anticipated timeframe or at all; the regulatory approvals required for the proposed transaction not being obtained on the terms expected or on the anticipated schedule or at all; inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements and the providing of estimates of financial measures, in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and related standards or on an adjusted basis (“Non-GAAP measures”); the integration of Mylan and Newco being more difficult, time consuming or costly than expected; Mylan’s, the Upjohn Business’s and the combined company’s failure to achieve expected or targeted future financial and operating performance and results; the possibility that the combined company may be unable to achieve expected benefits, synergies and operating efficiencies in connection with the proposed transaction within the expected time frames or at all or to successfully integrate Mylan and Newco; customer loss and business disruption being greater than expected following the proposed transaction; the retention of key employees being more difficult following the proposed transaction; any regulatory, legal or other impediments to Mylan’s, the Upjohn Business’s or the combined company’s ability to bring new products to market, including but not limited to where Mylan, the Upjohn Business or the combined company uses its business judgment and decides to manufacture, market and/or sell products, directly or through third parties, notwithstanding the fact that allegations of patent infringement(s) have not been finally resolved by the courts (i.e., an “at-risk launch”); success of clinical trials and Mylan’s, the Upjohn Business’s or the combined company’s ability to execute on new product opportunities; any changes in or difficulties with Mylan’s, the Upjohn Business’s or the combined company’s manufacturing facilities, including with respect to remediation and restructuring activities, supply chain or inventory or the ability to meet anticipated demand; the scope, timing and outcome of any ongoing legal proceedings, including government investigations, and the impact of any such proceedings on Mylan’s, the Upjohn Business’s or the combined company’s consolidated financial condition, results of operations and/or cash flows; Mylan’s, the Upjohn Business’s and the combined company’s ability to protect their respective intellectual property and preserve their respective intellectual property rights; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the ability to attract and retain key personnel; changes in third-party relationships; actions and decisions of healthcare and pharmaceutical regulators; the impacts of competition; changes in the economic and financial conditions of the Upjohn Business or the business of Mylan or the combined company; uncertainties regarding future demand, pricing and reimbursement for our, the Upjohn Business’s or the combined company’s products; and uncertainties and matters beyond the control of management and other factors described under “Risk Factors” in each of Pfizer’s and Mylan’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission (“SEC”). These risks, as well as other risks associated with Mylan, the Upjohn Business, the combined company and the proposed transaction are also more fully discussed in the Registration Statement on Form S-4, as amended, which includes a proxy statement/prospectus (the “Form S-4”), and Form 10, as amended, which includes an information statement (the “Form 10”), each of which has been filed by Newco with the SEC on October 25, 2019 and amended on December 13, 2019; and has not yet been declared effective. You can access Pfizer’s, Mylan’s and Newco’s filings with the SEC through the SEC website at www.sec.gov or through Pfizer’s or Mylan’s website, as applicable, and Pfizer and Mylan strongly encourage you to do so. Except as required by applicable law, Pfizer, Mylan and Newco undertake no obligation to update any statements herein for revisions or changes after the communications on this website are made.
Additional Information and Where to Find It

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. In connection with the proposed transaction, Newco and Mylan have filed certain materials with the SEC, including, among other materials, the Form S-4 and Form 10 filed by Newco. The registration statements have not yet become effective. After the Form S-4 is effective, a definitive proxy statement/prospectus will be sent to the Mylan shareholders seeking approval of the proposed transaction, and after the Form 10 is effective, a definitive information statement will be made available to the Pfizer stockholders relating to the proposed transaction. Newco and Mylan intend to file additional relevant materials with the SEC in connection with the proposed transaction, including a proxy statement of Mylan in definitive form. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT MYLAN, NEWCO AND THE PROPOSED TRANSACTION. The documents relating to the proposed transaction (when they are available) can be obtained free of charge from the SEC’s website at www.sec.gov. These documents (when they are available) can also be obtained free of charge from Mylan, upon written request to Mylan, at (724) 514-1813 or investor.relations@mylan.com or from Pfizer on Pfizer’s internet website at https://investors. Pfizer.com/financials/sec-filings/default.aspx or by contacting Pfizer’s Investor Relations Department at (212) 733-2323, as applicable.

Participants in the Solicitation

This communication is not a solicitation of a proxy from any investor or security holder. However, Pfizer, Mylan, Newco and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction under the rules of the SEC. Information about the directors and executive officers of Pfizer may be found in its Annual Report on Form 10-K filed with the SEC on February 28, 2019 and its definitive proxy statement and additional proxy statement relating to its 2019 Annual Meeting filed with the SEC on March 14, 2019 and on April 2, 2019, respectively, and Current Report on Form 8-K filed with the SEC on June 27, 2019. Information about the directors and executive officers of Mylan may be found in its amended Annual Report on Form 10-K filed with the SEC on April 30, 2019, and its definitive proxy statement relating to its 2019 Annual Meeting filed with the SEC on May 24, 2019. Additional information regarding the interests of these participants can also be found in the Form S-4 and will also be included in the definitive proxy statement of Mylan in connection with the proposed transaction when it becomes available. These documents (when they are available) can be obtained free of charge from the sources indicated above.

Non-GAAP Financial Measures

This communication includes the presentation and discussion of certain financial information that differs from what is reported under U.S. GAAP. These Non-GAAP measures, including, but not limited to, Adjusted EBITDA, Adjusted EBITDA margin and debt to credit agreement Adjusted EBITDA leverage ratio, are presented in order to supplement investors’ and other readers’ understanding and assessment of the financial performance of Mylan and the expected financial performance of the combined company following the consummation of the proposed transaction. The stated forward-looking Non-GAAP measure, targeted long-term average debt to credit agreement Adjusted EBITDA leverage ratio, is based on the ratio of (i) targeted long-term average debt, and (ii) targeted long-term credit agreement Adjusted EBITDA. However, Mylan has not quantified future amounts to develop the target but has stated its goal to manage long-term average debt and adjusted earnings and EBITDA over time in order to generally maintain the target. The target does not reflect Mylan guidance. Non-GAAP measures should be considered only as supplements to, not as substitutes for or as superior measures to, the measures of financial performance prepared in accordance with U.S. GAAP.
Speakers

Robert Coury  
*Executive Chairman*

- As VIATRIS’ Executive Chairman, will lead the Board and strategic direction of the Company; oversee the transition and future integration of the new management team; and mentor and drive the management team to execute on the Company’s strategy to deliver strong performance and growth.
- Experienced board chair who has been the principal architect of the transformation of Mylan through his direction of a series of transformative acquisitions over the last 17 years.
- Currently Chairman, Mylan N.V.

Michael Goettler  
*Chief Executive Officer*

- As Chief Executive Officer, will lead VIATRIS and be responsible for the execution of the Company’s strategy.
- Seasoned and talented pharma executive with strong leadership skills, international expertise and deep industry knowledge.
- Currently Global President, Upjohn

Rajiv Malik  
*President*

- As President of VIATRIS, will report to the CEO and oversee day-to-day operations and serve as a complementary partner to Michael.
- Unique profile as a scientist, who also possesses operational and commercial expertise, along with strong financial acumen.
- Currently President, Mylan N.V.
Empowering people worldwide to live healthier, at every stage of life.
The New Reality…

What the World is Facing

- Greater portion of the World’s population with medical needs (i.e. aging population, growing middle class)
- Growing disease cost burden, increasing budget pressures and limited access to medicines
- Coupled with a need to better understand and access …
- Growing number of innovations and medicines across wide array of diseases and modalities
- New digital/data/technology opportunities to deliver healthcare outcomes at reduced costs

What the Marketplace Needs

- Broad portfolio across geographies and therapeutic areas/diseases and technologies
- Focused innovation to improve health outcomes
  - Across all disease states
  - Across biology, medicine and digital/technology
  - Across partners and stakeholders
- Affordable and sustainable supply of high quality medicines
…A New Kind of Global Player

VIATRIS

ACCESS

LEadership

PARTNERSHIP
…With a Powerful Foundation

Global Footprint in US, Europe and Asia Markets

Diverse Portfolio Across all Key Therapeutic Areas

Best-in-Class Global Manufacturing and Supply Platform

Strong Cash Flow Profile Plus Sustainable Pipeline Engine

Enhanced Global Scale and Geographic Reach

Sustainable, Diverse and Differentiated Portfolio and Pipeline

Powerful Operating Platform / Commercial Capabilities and Ability to Extend Profitable Product Life Cycle

Enhanced, Sustainable Cash Flows Anticipated, Enabling Shareholder Friendly Capital Allocation

In Addition to Presence in Developed Markets, Uniquely Scaled Footprint in Asia and the Emerging Markets

Trusted, Iconic Off-Patent Brands

Best-in-Class Global Commercial Capabilities

Strong Cash Flow Profile

= Creation of A New Global Healthcare Gateway
Empowering people worldwide to live healthier, at every stage of life

VIATRIS Will Offer a Unique Global Healthcare Gateway

Partner of Choice
Creating better value for all stakeholders
...and Unparalleled Global Reach

Enables VIATRIS to Deliver Products Across Multiple Channels

Global Commercial Platform

- 165+ Countries & Territories
- 1,100+ Marketing professionals
- 60,000+ Customers
- 1,400+ Molecules
- 13,000+ Sales force
- ~30,000 SKUs
...Delivered Through a Unique Global Platform

Truly Global Supply Network
with local proximity

Strong Technical Resources
R&D, Quality, Medical, PV, & Regulatory across the globe

Optimized Operating and Medical Capabilities

~50 Manufacturing sites
60+ Distribution Networks
35,000+ Marketing Authorizations
135+ Annual Health Authorities inspections

80B+ Doses produced
2,500+ Scientists
1,000+ Regulatory experts
600+ Medical & Product Safety Professionals

Illustrative, not comprehensive
Fueling Our Future Growth

A Focus on Actively Expanding Innovative Partnerships

Significant partnership track record of leveraging each other’s capabilities and strengths
A Proven Track Record of Addressing Unmet Needs Through Complex Science

Complex Injectable
Glatiramer Acetate Injection (Copaxone)

Biosimilars
Pegfilgrastim (Neulasta)
Trastuzumab (Herceptin)
Adalimumab (Humira)

NCE
Revfenacian (Yupelri)

Insulin
Giargine (Lantus)

DPI Respiratory
Fluticasone propionate / Salmeterol (Advair)

Continuing to Execute Up the Value Continuum

Targeting ~$3B in New Revenue from Products Expected to Launch by Year 4

~2/3 Will be Complex Gx, Biosimilars and Global Key Brands

Product examples illustrative, not exhaustive

* Molecules in development, not yet publicly identified
Sustainable, Diverse and Differentiated Portfolio

- Brand 56%
- U.S. Generic 15%
- Ex-U.S. Generic 19%
- OTC 6%
- Biologics 4%

Expected Combined Revenue
**Synergies**

**Cost Synergies: Expected to Achieve ~$1bn Annually by Year Four**

- **S&M**
  - ~40% of total
  - Key Areas
    - Transition Services Agreement
    - Elimination of Duplicate Infrastructure

- **G&A**
  - ~40% of total
  - Key Areas
    - Transition Services Agreements
    - Elimination of Duplicate Infrastructure
    - Cost Avoidance
    - No Standalone / Corporate Build-up Costs

- **COGS**
  - ~20% of total
  - Key Areas
    - Optimization of Network
    - Manufacturing and Supply Agreements
    - Procurement
    - Transition Services Agreements

**Revenue Synergies Expected After Year One**

- Select Product Opportunities Based on Synergistic Portfolio in Emerging Markets and Asia Pacific
- Cross Pollinate Global Key Brands Across Portfolios
- Launch New Products
- Expand Access and Reach for Global Partners
- Enhance Commercial Excellence
Stronger Business Model

Transformational combination strengthens balance sheet, enhances financial flexibility and transitions to a shareholder return focused capital allocation model.

<table>
<thead>
<tr>
<th>Financial Flexibility</th>
<th>Mylan</th>
<th>Viatris</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leverage Target: 3.0x⁠¹</td>
<td></td>
<td>Leverage Target: ≤2.5x</td>
</tr>
<tr>
<td>Dividend</td>
<td>No dividend</td>
<td>Expected dividend ≥ 25% of free cash flow beginning first full quarter after close of proposed transaction (est. to close mid-2020)</td>
</tr>
<tr>
<td>Repurchase</td>
<td>Prioritizing debt paydown over share repurchases</td>
<td>Significant financial capacity to repurchase shares in addition to paying down debt</td>
</tr>
<tr>
<td>Structural</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Domicile</td>
<td>Netherlands (Stakeholder-centric model)</td>
<td>Delaware (Shareholder-centric model)</td>
</tr>
<tr>
<td>Management</td>
<td>Strong and cohesive current management team</td>
<td>Deep bench strength that combines the complementary skill sets of Mylan and Upjohn</td>
</tr>
</tbody>
</table>

¹ Reflects Mylan’s targeted long-term average debt to credit agreement Adjusted EBITDA leverage ratio.
Clear Roadmap of Execution to Optimize Total Shareholder Return (TSR)

Transaction Close

<table>
<thead>
<tr>
<th>Years</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operations</td>
<td>INTEGRATION</td>
<td>COST SYNERGIES</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Pipeline Launches</td>
<td>PRODUCT LAUNCHES ~$3bn</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synergies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leverage</td>
<td>RAPID DELEVERAGING</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capital Return</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capital Allocation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Pipeline Investment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Business Development</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- INTEGRATION
- PRODUCT LAUNCHES ~$3bn
- COST SYNERGIES
- REVENUE SYNERGIES
- RAPID DELEVERAGING
- SHARE REPURCHASES
- DIVIDENDS
## Expected Attractive Financial Profile

### Selected Large Cap Pharma vs. VIATRIS vs. Selected Spec Pharma / Generics

<table>
<thead>
<tr>
<th>Market Cap ($bn)</th>
<th>Selected Large Cap Pharma</th>
<th>VIATRIS</th>
<th>Selected Spec Pharma / Generics</th>
</tr>
</thead>
<tbody>
<tr>
<td>$227</td>
<td>$216</td>
<td>~$25¹</td>
<td>$15</td>
</tr>
<tr>
<td>$143</td>
<td>$132</td>
<td>~$143</td>
<td>$11</td>
</tr>
<tr>
<td>$132</td>
<td>$119</td>
<td>~$132</td>
<td>$10</td>
</tr>
<tr>
<td>$119</td>
<td></td>
<td>$119</td>
<td>$7</td>
</tr>
<tr>
<td>$143</td>
<td></td>
<td>$143</td>
<td>$6</td>
</tr>
<tr>
<td>$132</td>
<td></td>
<td>$132</td>
<td>$1</td>
</tr>
</tbody>
</table>

### 2020E EBITDA Margin

- 43% (Pfizer)
- 34% (Novartis)
- 55% (Amgen)
- 35% (Lilly)
- 32% (Glaxo)

### Average Estimated Gross Debt / 2020E EBITDA

- ~2x

### Pays Dividend / Dividend Yield

- 3.6% (Pfizer)
- 3.1% (Lilly)
- 2.4% (Amgen)
- 1.9% (Novartis)
- 4.5% (Glaxo)

### TEV / 2020E EBITDA

- ~12x
- ~14x⁸
- ~12x⁹
- ~17x¹⁰
- ~11x

### VIATRIS Financials

- More Balanced Risk Profile
- Robust Balance Sheet

### What multiple will VIATRIS deserve?

- ~14x
- ~8x
- ~10x
- ~10x
- ~10x

### Source: Company filings, Capital IQ.

1 Assumes estimated pro forma shares of 1.215bn and Mylan price per share as of 01/10/2020; 2 Wall Street consensus 2020E EBITDA margin. Figures adjusted to reflect 2020E calendar year; 3 Gross leverage multiples based on consensus EBITDA estimates and gross debt outstanding as of the last reported publicly available filings. EBITDA estimates adjusted to reflect 2020E calendar year; 4 Dividend per share declared in the last 12 months divided by the company share price dated 01/10/2020; 5 Wall Street consensus adjusted EBITDA margin including phased-in synergies; 6 Estimated pro forma 2020E free cash flow paid as dividend, divided by pro forma share count of 1.215bn; 7 2020E pro forma adjusted EBITDA margin including phased-in synergies and adjusted for $4bn of pro forma 2020E free cash flow paid as dividend. Figures adjusted to reflect 2020E calendar year; 8 Dividend per share declared in the last 12 months divided by the company share price dated 01/10/2020; 9 2020E pro forma adjusted EBITDA margin including phased-in synergies and adjusted for $4bn of pro forma 2020E free cash flow paid as dividend. Figures adjusted to reflect 2020E calendar year; 10 Dividend per share declared in the last 12 months divided by the company share price dated 01/10/2020; 11 Consensus estimates are not internal estimates; 12 Includes $9.7bn cash impact from acquiring The Medicines Company; 13 Includes $13.4bn cash impact from acquiring Celgene's Otezla; 14 Includes $1.1bn cash impact from acquiring Dermira.

---

**Creates a Differentiated Industry Leader with a Strong Financial Profile and Opportunities to Deliver Substantial Shareholder Returns**
### Potential Opportunity to Deliver Significant Shareholder Value

In addition to returning significant capital to shareholders, **VIATRIS** has the opportunity to unlock shareholder value through multiple expansion.

<table>
<thead>
<tr>
<th>Illustrative Total Enterprise Value / EBITDA</th>
<th>Implied VIATRIS Share Price(^1)</th>
<th>Illustrative VIATRIS EBITDA ($bn)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.0x</td>
<td>$20</td>
<td>$20, $23, $26, $29</td>
</tr>
<tr>
<td>8.0x</td>
<td>$26</td>
<td>$26, $29, $32, $36</td>
</tr>
<tr>
<td>9.0x</td>
<td>$31</td>
<td>$31, $35, $39, $43</td>
</tr>
<tr>
<td>10.0x</td>
<td>$37</td>
<td>$37, $41, $45, $50</td>
</tr>
<tr>
<td>11.0x</td>
<td>$43</td>
<td>$43, $48, $52, $57</td>
</tr>
</tbody>
</table>

**Note:** Share price rounded to the nearest dollar.

1 Assumes net debt of $24.8bn including $12bn Upjohn contributed debt, $13bn standalone Mylan debt, $0.4bn standalone Mylan cash (as of Q3 2019) and pro forma share count of 1.215bn.
On-Track for Mid-2020 Close

- Ongoing Integration Planning
- Announce New Company Name
- Determined that VIATRIS will be Listed on Nasdaq
- Commenced VIATRIS Director Appointments
- Announce VIATRIS Chief Financial Officer
- Receive Mylan Shareholder Approval
- Receive Regulatory Approvals Across Jurisdictions, including U.S., EC and China
- Complete Other Customary Closing Conditions
- Transaction Expected to Close Mid-2020